JP2018509458A5 - - Google Patents

Download PDF

Info

Publication number
JP2018509458A5
JP2018509458A5 JP2017550542A JP2017550542A JP2018509458A5 JP 2018509458 A5 JP2018509458 A5 JP 2018509458A5 JP 2017550542 A JP2017550542 A JP 2017550542A JP 2017550542 A JP2017550542 A JP 2017550542A JP 2018509458 A5 JP2018509458 A5 JP 2018509458A5
Authority
JP
Japan
Prior art keywords
theta
crystal
xrpd pattern
peaks
dsc thermogram
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017550542A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018509458A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/024321 external-priority patent/WO2016160604A1/en
Publication of JP2018509458A publication Critical patent/JP2018509458A/ja
Publication of JP2018509458A5 publication Critical patent/JP2018509458A5/ja
Pending legal-status Critical Current

Links

JP2017550542A 2015-03-27 2016-03-25 ブルトン型チロシンキナーゼ阻害剤の共結晶 Pending JP2018509458A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562139599P 2015-03-27 2015-03-27
US62/139,599 2015-03-27
PCT/US2016/024321 WO2016160604A1 (en) 2015-03-27 2016-03-25 Co-crystals of a bruton's tyrosine kinase inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021009155A Division JP2021075540A (ja) 2015-03-27 2021-01-22 ブルトン型チロシンキナーゼ阻害剤の共結晶

Publications (2)

Publication Number Publication Date
JP2018509458A JP2018509458A (ja) 2018-04-05
JP2018509458A5 true JP2018509458A5 (enExample) 2019-05-09

Family

ID=57006345

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017550542A Pending JP2018509458A (ja) 2015-03-27 2016-03-25 ブルトン型チロシンキナーゼ阻害剤の共結晶
JP2021009155A Pending JP2021075540A (ja) 2015-03-27 2021-01-22 ブルトン型チロシンキナーゼ阻害剤の共結晶
JP2022111272A Pending JP2022160433A (ja) 2015-03-27 2022-07-11 ブルトン型チロシンキナーゼ阻害剤の共結晶

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021009155A Pending JP2021075540A (ja) 2015-03-27 2021-01-22 ブルトン型チロシンキナーゼ阻害剤の共結晶
JP2022111272A Pending JP2022160433A (ja) 2015-03-27 2022-07-11 ブルトン型チロシンキナーゼ阻害剤の共結晶

Country Status (11)

Country Link
US (3) US20180072739A1 (enExample)
EP (1) EP3273962A4 (enExample)
JP (3) JP2018509458A (enExample)
CN (1) CN107530347A (enExample)
AU (1) AU2016243122A1 (enExample)
BR (1) BR112017020743A2 (enExample)
CA (1) CA2981046A1 (enExample)
HK (2) HK1249736A1 (enExample)
MA (1) MA41828A (enExample)
MX (1) MX2017012411A (enExample)
WO (1) WO2016160604A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201492082A1 (ru) 2012-06-04 2015-03-31 Фармасайкликс, Инк. Кристаллические формы ингибитора тирозинкиназы брутона
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
JP6705833B2 (ja) * 2015-04-02 2020-06-03 ラティオファルム ゲー・エム・ベー・ハー イブルチニブとカルボン酸との共結晶
US10183024B2 (en) 2016-12-02 2019-01-22 Apotex Inc. Crystalline forms of ibrutinib
WO2019070698A1 (en) 2017-10-02 2019-04-11 Johnson Matthey Public Limited Company Novel forms of ibrutinib
CN109776543A (zh) * 2017-11-14 2019-05-21 上海医药工业研究院 依鲁替尼盐、其晶体、制备方法、药物组合物及应用
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
WO2019195827A1 (en) 2018-04-06 2019-10-10 Johnson Matthey Public Limited Company Novel form of ibrutinib
EP3575300A1 (en) 2018-05-31 2019-12-04 Apotex Inc. Novel crystalline forms of ibrutinib
CN112292117B (zh) 2018-06-15 2024-06-07 詹森药业有限公司 包含依鲁替尼的配制品/组合物
BR112021015796A2 (pt) * 2019-02-13 2021-10-13 Prelude Therapeutics, Incorporated Inibidor seletivo de proteína arginina metiltransferase 5 (prmt5)
NL2027668B1 (en) 2020-02-28 2022-06-03 Yeti Cycling Llc 6-bar vehicle suspension linkage with drive train idler
WO2021212253A1 (zh) * 2020-04-20 2021-10-28 天津睿创康泰生物技术有限公司 伊布替尼葡糖糖酸内酯共晶体及其制备方法
US20230338315A1 (en) * 2020-08-14 2023-10-26 Board Of Regents, The University Of Texas System Method of producing pharmaceutical cocrystals for additive manufacturing
CN114685512B (zh) * 2020-12-31 2022-11-29 鲁南制药集团股份有限公司 一种伊布替尼-烟酸共晶及其制备方法
WO2023242384A1 (en) 2022-06-17 2023-12-21 Krka, D.D., Novo Mesto Crystalline form of ibrutinib
CN115417812B (zh) * 2022-08-05 2024-04-05 天津大学 一种阿西替尼-烟酰胺共晶及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
JP2527107B2 (ja) 1991-04-16 1996-08-21 日本新薬株式会社 固体分散体の製造方法
CZ282760B6 (cs) 1991-11-22 1997-09-17 Procter And Gamble Pharmaceuticals, Inc. Risedronátové prostředky se zpožděným uvolňováním
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
EP0665010B1 (en) 1992-10-16 2002-09-11 Nippon Shinyaku Company, Limited Method of manufacturing wax matrices
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
JPH11505258A (ja) 1995-05-17 1999-05-18 セダーシナイ メディカル センター 小腸における消化および吸収を改善させる脂肪酸を含む組成物
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6921763B2 (en) * 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
US7711492B2 (en) 2003-09-03 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Methods for diagnosing lymphoma types
EP2526934B1 (en) 2006-09-22 2015-12-09 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
SG10202107066WA (en) * 2007-03-28 2021-07-29 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
EP2123626A1 (en) * 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-crystals of duloxetine and co-crystal formers for the treatment of pain
MX2011004759A (es) * 2011-05-04 2012-11-21 Senosiain S A De C V Lab Nuevas formas solidas de antibioticos.
EA201492082A1 (ru) * 2012-06-04 2015-03-31 Фармасайкликс, Инк. Кристаллические формы ингибитора тирозинкиназы брутона
PL2892900T3 (pl) * 2012-09-10 2018-02-28 Principia Biopharma Inc. Związki pyrazolopirymidonowe jako inhibitory kinazy
GB201309085D0 (en) * 2013-05-20 2013-07-03 Redx Pharma Ltd Compounds
WO2015034478A1 (en) * 2013-09-04 2015-03-12 Halliburton Energy Services, Inc. Scale-inhibiting cocrystals for treatment of a subterranean formation
WO2015038887A1 (en) * 2013-09-12 2015-03-19 Dana-Farber Cancer Institute Inc. Methods for evaluating and treating waldenstrom's macroglobulinemia
CN104447701B (zh) 2013-09-17 2019-03-22 广东东阳光药业有限公司 吡唑类衍生物及其用途
JP6705833B2 (ja) 2015-04-02 2020-06-03 ラティオファルム ゲー・エム・ベー・ハー イブルチニブとカルボン酸との共結晶

Similar Documents

Publication Publication Date Title
JP2018509458A5 (enExample)
JP2018509457A5 (enExample)
JP2014515013A5 (enExample)
Swapna et al. Cocrystals of the tuberculosis drug isoniazid: polymorphism, isostructurality, and stability
NZ737725A (en) Crystalline forms of a bruton’s tyrosine kinase inhibitor
HRP20220371T1 (hr) 1,3-tiazol-2-il supstituirani benzamidi
JP2016508155A5 (enExample)
MX2020014086A (es) Compuestos de aminoácidos con ligadores no ramificados y métodos de uso.
JP2015509973A5 (enExample)
HRP20151299T1 (hr) Kristalni (r)-(e)-2-(4-(2-(5-(1-(3,5-diklorpiridin-4-il)etoksi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol i njegova upotreba kao inhibitora fgfr
RU2015143643A (ru) Соль омекамтива мекарбила и способ ее получения
FI3102208T4 (fi) 2-hydroksi-6-((2-(1-isopropyyli-1h-pyratsol-5-yyli)pyridin-3-yyli)metoksi)bentsaldehydin vapaan emäksen kiteinen polymorfi
JP2015522037A5 (enExample)
HRP20241280T1 (hr) Kruti oblici rukapariba i soli rukapariba
CN112368281A (zh) 作为pde3/pde4双重抑制剂的三并环类化合物
JP2015523385A5 (enExample)
RU2010101795A (ru) Аминовые соли антагониста crth2
JP2015535287A5 (enExample)
MX2014014105A (es) Compuestos de pirazol sustituidos como antagonistas del receptor del acido lisofosfatidico (lpar).
JP2016108545A5 (enExample)
CN104039793A (zh) 二氢吡咯并[1,2-c]咪唑基醛固酮合成酶或芳香酶抑制剂的新形式及盐
JP2016537326A5 (enExample)
RU2019105794A (ru) Кристаллогидрат соединения (2s, 3r) -изопропил 2 - (((2- (1,5-диметил-6-оксо-1,6-дигидропиридин-3-ил) -1 - ((тетрагидро-2h-пиран) -4-ил) метил) -1h-бензо [d] имидазол-5-ил) метил) амино) -3-гидроксибутаноат эдисилат
RU2019112080A (ru) Соли производного индазола и их кристаллы
JP2015506987A5 (enExample)